lung cancer

News

Anne Wojcicki, CEO and co-founder of 23andMe

23andMe board rebuffs CEO plan to take the firm private

A proposal by 23andMe founder and chief executive Anne Wojcicki to take the genetic testing company private has been rejected by a special committee of the board of directors.

Oncology

Paul Burton interview with Jonah Comstock

ASCO 2024 - Paul Burton

For Amgen, ASCO 2024 was all about lung cancer, with encouraging data in both non-small cell and small cell lung cancer.

Oncology

Four takeaways from ASCO24

Last weekend, I travelled to Chicago for the annual conference of the American Society of Clinical Oncologists— the annual event where major breakthroughs in cancer care are announced.

News

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan i

News

AZ, Daiichi eye December verdict for TROP2 ADC

The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC

News

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating

23andMe board rebuffs CEO plan to take the firm private

ASCO 2024 - Paul Burton

Four takeaways from ASCO24

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

AZ, Daiichi eye December verdict for TROP2 ADC

Tagrisso-chemo cleared in US as 1st-line lung cancer therapy

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks